Immuno-oncology company Agenus Inc (NASDAQ: AGEN) reported on Tuesday the receipt of the US FDA clearance for the IND application for an allogeneic iNKT therapy as the potential therapy for patients in moderate to severe respiratory distress from COVID-19.
The company stated that AgenT-797 was submitted by its subsidiary, AgenTus Therapeutics.
Following the FDA clearance, the clinical trial of the allogeneic iNKT therapy for the treatment of patients with COVID-19 is expected to commence shortly. the company previously reported the FDA clearance of the IND for the use of allogeneic iNKTs for patients with cancer.
In conjunction, Dr Koen van Besien at Weill Cornell/New York Presbyterian Hospital will lead the COVID-19 trials.
By the end of this year, the company is contemplating of spinning out of AgenTus as well as issuing a portion of its holdings in AgenTus to Agenus shareholders in the form of a stock dividend.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development